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A phase I and pharmacologic study of Belotecan in combination 
with Cisplatin in patients with previously untreated extensive-stage 
disease small-cell lung cancer
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Background: Belotecan (Camtobell®; CKD602) is a novel campto-
thecin derivative antitumor agent. This phase I study was designed to 
determine the maximum-tolerated dose (MTD), toxicity proﬁle, and 
dose-limiting toxicity (DLT) of belotecan in combination with cisplatin 
in patients with previously untreated extensive-stage disease small-cell 
lung cancer (ED SCLC). Furthermore, pharmacokinetics (PK) and pre-
liminary antitumor activity of belotecan against SCLC were evaluated.
Methods: Patients with ED SCLC, age 18-70, ECOG PS 0-2, no prior 
chemotherapy and adequate organ function were eligible. Cisplatin 
with ﬁxed dose of 60 mg/m2 was administered intravenously (i.v.) over 
2 hours on day 1. Belotecan was administered iv as intermittent 30-
minute infusions on days 1 to 4, starting dose of 0.40 mg/m2/day with 
increment of 0.05 mg/m2/day. Modiﬁed Fibonacci escalation was used 
(3 to 6 patients per cohort) and intra-patient dose escalation was not al-
lowed. PK of belotecan was determined during the ﬁrst treatment using 
non-compartmental pharmacokinetic analysis.
Results: Seventeen patients were treated at 4 dose levels (0.40 to 
0.55 mg/m2/day). At 0.55 mg/m2/day of belotecan, the DLT of grade 
4 neutropenia with fever occurred in 2 of 5 patients, and therefore the 
MTD was 0.50 mg/m2/day. Interestingly, out of 17 patients, there were 
14 partial responses (82.4%; 95% CI, 63.4% to 100.0%). PK analysis 
revealed that at 0.50 mg/m2/day, plasma clearance of belotecan was 
5.78 ± 1.32 L/hr and terminal half-life was 8.55 ± 2.12 hr. Fraction of 
excreted amount in urine was 37.36 ± 5.55 %. PK of belotecan were 
not altered by administration of cisplatin, as compared with historical 
control.
Conclusions: The MTD of belotecan was 0.50 mg/m2/day for intermit-
tent 30-min i.v. infusion for 4 days in combination with cisplatin 60 
mg/m2 on day 1 every 3 weeks. Furthermore, very promising antitu-
mor activity against SCLC was observed. The phase II study is being 
conducted now.
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Purpose: Early high-dose chemotherapy was tested in different non-
randomized trials with impressive complete response rate, and over 
the years this approach continued to be proposed without the possibil-
ity to obtain ﬁrm conclusions, but in submitting cohorts of patients to 
signiﬁcant toxicities. The early administration of multiple and sequen-
tial high-dose chemotherapy supported by peripheral blood progenitors 
allowed to increase the dose intensity of chemotherapy by three fold. 
The EBMT carried out a randomized trial to test the impact of such an 
intensiﬁcation on long-term survival of patients with small cell lung 
cancer.
Methods: Patients with limited and extensive disease with ≤2 meta-
static sites were randomized to 6 cycles of standard dose ICE (ifos-
famide 5 g/m2, carboplatin 300 mg/m2, and etoposide 360 mg/m2 over 2 
days every 28 days) or 3 cycles of high-dose ICE (ifosfamide 10 g/m2, 
carboplatin AUC 20, etoposide 1200 mg/m2, all drugs divided over 4 
days, every 28 days) supported by PBPCs previously collected follow-
ing 2 cycles of epidoxorubicin 150 mg/m2 and paclitaxel 175 mg/m2 
and ﬁlgrastim. Due to a low accrual rate an interim analysis was carried 
out with strong boundaries that allowed to close the trial prematurely 
and to obtain ﬁrm and ﬁnal conclusions. 
Results: The median relative dose intensity of the high-dose ICE was 
293% (174% to 392%) compared to the standard ICE. The 3- year 
survival rate was 18% and 19% in the high-dose and standard dose arm 
respectively. The median survival rate were not statistically differ-
ent(18.1 months and 14.4 months), neither the overall (78% and 68%) 
and complete response rate (39% and 34%). An analysis according 
to stratiﬁcation factors (limited vs extensive disease, LDH normal vs 
abnormal, male vs female, PS 0 vs 1) could not disclose any subgroups 
that beneﬁted from the intensive strategy. Hematological toxicity was 
signiﬁcant in the standard arm (grade >3 neutropenia 70%, anemia 
25%, thrombopenia 25%) associated with a toxic death rate at 4%. In 
the high-dose arm, beside the expected severe myelosuppression, the 
toxic death rate was at 10% and the median hospitalization time was 20 
days compared to 4 days for the standard treatment.
Conclusions: Despite an increase in the peak dose, the total dose and 
the dose-intensity by 3 fold ICE chemotherapy did not improve the 
long term outcome of SCLC but was toxic and expensive. This stategy 
should be abandoned.
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(SCLC) with extensive disease (ED)
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Background: Standard treatment for ED achieves a median suvival 
time of 9 months with only 1-2% of long survivors. Biweekly sched-
ules have demostrated to be convenient for patients (pts) with different 
cancers. We assessed the eﬁcacy and toxicity of a biweekly combina-
tion of Cb and G in chemonaïve pts.
Methods: We included pts with ED or limited disease unﬁt for com-
bined radical radiotherapy with ECOG PS 0-2. Pts with brain metasta-
sis were also enrolled. Treatment consisted of: Cb AUC 3 day 1 and G 
2000 mg/m2 day 1 every 14 days, ﬁnal response was assessed after 8 
cycles
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Results: Since today 20 pts have been enrolled. Median age was 59 
yrs (44-74). 17 males and 3 females. PS1 65% and PS 2 30%. All but 
two had ED. Median number of metastatic sites was 2 (1-5), including 
2 pts with brain metastasis. Median number of cycles was 8 (1-12). A 
total of 133 cycles were administered. Considering all cycles, WHO 
grade 3 and 4 toxicity was as follows: neutropenia 3%, with no febrile 
neutropenia, thrombocytopenia 1%, anemia 3%. There was not grade 
3-4 non-hematological toxicity. In an ITT analysis overall response rate 
was 60% (12/20) including 20% (4/20) complete responses. At time of 
this analysis 55% of pts were dead and Kaplan Meyer actuarial suvival 
was 47,1 weeks (95% CI: 27-67). The 1 year suvival rate was 39 %.
Conclusions: Biweekly Cb plus G is a feasible and active regimen as 
ﬁrst line chemotherapy for pts with metastatic SCLC. Median suvival 
time seems to be in the range of other regimens commonly used. Our 
results show this schedule convenient for pts in a palliative outpatient 
setting.
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Background: The intravenous (IV) method of cytotoxic chemotherapy 
administration imposes not only a time burden on patients and facili-
ties, but also has cost implications for payers. This study aims to assess 
the costs associated with the IV administration of chemotherapies 
for patients with all forms of lung cancer and for a subset of patients 
with small cell lung cancer (SCLC) in a large employer-payer claims 
database.
Methods: Using medical claims data from 5.5 million beneﬁciaries 
between 01/01/1998 and 01/31/2006, we identiﬁed 8,605 patients with 
lung cancer (ICD-9 codes 162.3-162.9, 176.4, or 197.0) receiving IV 
chemotherapies. We then identiﬁed a subset of 1,087 patients likely to 
have SCLC by selecting those receiving chemotherapy regimens princi-
pally used to treat SCLC (cisplatin/etoposide, cisplatin/irinotecan, car-
boplatin/etoposide, or topotecan) and excluding patients receiving PET 
scan imaging procedures associated with non-small cell lung cancer 
(NSCLC). Average total costs per day of IV chemotherapy administra-
tion (including drug, administration costs, etc.) were computed for 
all patients and for the SCLC subset based on the actual amount paid. 
Costs were also computed separately for: IV chemotherapy drugs, IV 
chemotherapy administration procedures, and other visit-related drugs 
and services (e.g., IV administration of other drugs to treat side effects 
of chemotherapies, evaluation and management, and laboratory tests). 
Results: Average total cost per day of IV chemotherapy administra-
tion for patients with all forms of lung cancer was $1,112, with $652 
(58.6%) attributable to IV chemotherapy drugs, $85 (7.7%) to IV 
chemotherapy administration procedures, and $375 (33.7%) to other 
visit-related drugs and services. Among patients with SCLC, average 
total daily cost was $841, with $451 (53.6%) attributable to IV chemo-
therapy drugs, $88 (10.5%) to IV chemotherapy administration, and 
$302 (35.9%) to other visit-related drugs and services. 
Conclusions: IV chemotherapy administration procedures and other 
visit-related drugs and services accounted for 41.4% and 46.4% of total 
costs in patients with all forms of lung cancer and those with SCLC, 
respectively. The increased availability and use of oral chemotherapy 
drugs in lung cancer should not only enhance patient convenience, but 
also provide savings to payers as costs associated with IV administra-
tion, and potentially other visit-related drugs and services, may be 
avoided.
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Background: SCLC is a highly symptomatic disease with poor 
survival in previously treated patients. To evaluate the role of chemo-
therapy, a multicenter trial randomized 141 previously treated patients 
to receive either OT + BSC or BSC only. This trial evaluated survival, 
response and symptoms. Median survivals were 25.9 weeks on OT 
+ BSC vs 13.9 weeks on BSC (p = 0.01) (O’Brien et al JCO 2006). 
“Disease control” (partial response [PR] + stable disease [SD]) was 
achieved by 51% of patients receiving OT + BSC; no patient on BSC 
was reported to have a major response, although response was not an 
endpoint for this group. In that symptomatic beneﬁt is a major goal 
beyond survival improvement in this difﬁcult setting, we undertook this 
analysis to determine if there is an additional value to major response 
versus stable disease in patients receiving OT chemotherapy.
Methods: The patient reported outcome instrument used in this trial 
was the PSALC (a measure of patient self-reported lung symptoms). 
Association between baseline PSALC total scores and ECOG perfor-
mance status (PS) was tested using a contrasted group analysis. We 
used the investigators evaluation of response (PR or SD) in the 71 pa-
tients on the OT arm and analyzed these groups by the patients’ PSALC 
total scores.
Results: Patients with a lower functional status based on ECOG PS 
at baseline reported more severe symptoms (higher PSALC score): 
mean PSALC score=12.31, 16.37, 17.58 for ECOG score=0, 1, 2, 
respectively, p=0.0002. Mean changes in PSALC score from baseline 
demonstrated an association between tumor response and symptom 
control (p=0.0016). For patients with PR (N=5), mean baseline PSALC 
was 15.07, while mean on-treatment PSALC was 12.64, representing a 
change from baseline of -2.43 and a 16.12% improvement in symp-
toms. In contrast, for patients with SD (N=31) there was no appreciable 
change in PSALC between baseline and on-treatment (mean PSALC 
was 15.33 and 15.35, respectively with change from baseline of 0.01). 
Conclusions: Patients who achieved a major response on OT treat-
ment reported signiﬁcantly better symptom relief than those whose best 
response was SD. In that the decision to treat in the second-line setting 
can be a difﬁcult one, these results indicate added symptomatic beneﬁt 
for patients able to achieve major response, which only occurs with 
treatment.
